NASDAQ: ILMN

Illumina (ILMN) Stock Analysis & Forecast

Nov 16 close

$198.00−9.01 (−4.4%)

Gekko Brief

AI summaryNov 16 close

This week's headlines around Illumina center on clinical sequencing demand and product development rather than a single catalyst. At the UBS Global Healthcare Conference, executives pointed to clinical demand and sequencing consumables as central to growth even as research customers face continued grant funding uncertainty. Separately, Illumina advanced its MRD research portfolio, launching an early access program for ultrasensitive duplex sequencing technology aimed at molecular residual disease and tumor evolution research, with reproducible detection of ctDNA at 2.5 parts per million in representative studies.

Illumina closed at $198.00, down 4.4%, with the one-month return at -24.6% against a six-month gain of 39.9% and a one-year gain of 65.1%. The close sits between the 50-day average of $248.62 and the 200-day average of $179.78, reflecting a mixed trend. The GekkoIndex reads 68.2, placing the stock in the Accumulation zone, up 3.8 over five periods. Price sits 22% below Gekko Fair Value of $253.99.

The next earnings date is 4 February 2027, 79 days out, after the last report on 29 October 2026 showed EPS of $1.62 against a $1.36 estimate, though shares reacted -18.3%. Over the last 30 days, one unusual options signal appeared, with call premium of $484,785 against put premium of $750,905. Seasonality over five years shows a 6.8% average 20-day return from this point, positive in 4 of those years. Analyst consensus across 17 firms includes 8 buy, 6 hold and 3 sell ratings, with a consensus target of $261.45.

Written by AI from the Nov 16, 2026 close and checked automatically against the figures on this page.

Illumina price vs fair value

$253.75$198.00Nov ’25May ’26Nov ’26
Close $198.00200-day averageGekko Fair Value $253.75

Illumina quick facts

Market cap
$29.94B
P/E ratio
35.6
Forward P/E
33.6
EPS, TTM
$5.81
Revenue, TTM
$4.54B
Profit margin
19.7%
Dividend yield
—
Beta
1.45
Volume
1.52M avg 2.19M
1-year return
+65.1%
Typical daily move
±8.4%
Typical 20-day move
±8.2%
50-day average
$248.62
200-day average
$179.78
Next earnings
Feb 4 after close
Shares outstanding
151.2M
52-week range
$112.65$309.35

Illumina swing-trade checklist

Illumina scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $198.00 sits between the 50-day ($248.62) and 200-day ($179.78) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    68.2, Accumulation

    Reading 68.2 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    22.0% below

    Price is 22% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyheadwind

    Leans bearish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 79 days

    Next report Feb 4, 2027, 79 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +8.5% on average

    From this point in the calendar, the next 20 trading days averaged +8.5% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Illumina stock chart and price history

Illumina closed at $198.00 on Nov 16, 2026, +65.1% over the past year, inside a 52-week range of $112.65 to $309.35.

Close50-day average200-day averageVolume
Illumina share price, past year, with 50-day and 200-day moving averages and volume$100$150$250$300DecJan 2026FebMarAprMayJunJulAugSepOctNov198.00

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−24.6%
3 months
+5.2%
6 months
+39.9%
1 year
+65.1%
The full ILMN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ILMN in Gekko

Follow Illumina through every session

Put ILMN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ILMN in GekkoFree for 7 days. No credit card required.

About Illumina

Illumina builds tools that read and interpret DNA, centering on sequencing and array technology. Its systems help laboratories and clinics turn genetic material into usable insight, supporting work in areas such as life sciences research, cancer diagnostics, reproductive health, and agriculture, along with newer areas of genomic study. The company is particularly associated with the instruments and related supplies that make this kind of large-scale genetic analysis possible.

Revenue comes from selling sequencing and genotyping instruments alongside the consumables they require, plus related services such as equipment servicing, licensing and development partnerships, and cancer screening tests. Customers include research institutions, universities, government and hospital laboratories, drug and biotech developers, diagnostic companies, and firms in consumer genomics. Illumina reaches these customers both by selling to them directly, across North America, Europe, Latin America and the Asia-Pacific, and through distributor partners who cover additional regions including the Middle East and Africa.

The company was founded in 1998 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker ILMN.

Listed
NASDAQ
Sector
Health technology
Industry
Medical specialties
Website
illumina.com

Illumina GekkoIndex: the smart money zone

Illumina’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.2, in the Accumulation zone, up 3.8 points over five sessions.

010068.2Accumulation

Up 3.8 points over five sessions.

Reading for Nov 16, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying52−1.4%−2.5%−4.0%−2.1%
Accumulation (current zone)172+0.5%−0.7%−1.0%+2.7%
Neutral424+0.9%+2.6%+4.6%+11.0%
Distribution58−0.1%−1.4%+3.2%+3.4%
Selling1Too few readings yet

Average ILMN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +1.9% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the ILMN price, zone by zone.Track ILMN in Gekko

Is Illumina stock overvalued? Gekko Fair Value

Illumina trades 22.0% below Gekko Fair Value of $253.75, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Illumina shares are worth, recalculated every trading day.

$253.75

Gekko Fair Value, Nov 17, 2026

22.0% Undervalued

At the end of Aug 2026 the price was 8.2% above the estimate.

Gekko Fair ValueShare price, month end
$254$198Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ILMN in Gekko

Illumina insider and Congress trading

No open-market insider purchases were filed for Illumina, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ILMN in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ILMN insider filing, plotted on the chart in Gekko.Open ILMN in Gekko

Congress trades last 90 days

No trades in ILMN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ILMN, plotted on the chart in Gekko.Open ILMN in Gekko

Buybacks

Illumina has been buying back its own shares.

Latest authorization
$1.50B, Apr 30, 2026
Bought back, quarter ended Sep 27, 2026
$9.00M
As a share of market cap
0.03%
Trailing four quarters
$535.0M

From company filings.

Unusual options activity last 30 days

1signal, 39% of the flagged premium in calls.

Latest: Bearish flow on Nov 3, $1.24M in unusual premium.

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold ILMN.

0added0opened0trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Illumina earnings: next date and track record

Illumina reports on Feb 4, 2027, after the close (79 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±12.5%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−10.9%Feb ’25−0.8%May ’25−11.3%Jul ’25+30.0%Oct ’25−10.8%Feb ’26+12.8%Apr ’26+5.3%Jul ’26−18.3%Oct ’26

Last earnings call, Oct 29, 2026 AI summary

What they said
Illumina reported Q3 2026 results above guidance range, driven by strong clinical sequencing demand and elevated NovaSeq X placements, with revenue, margin, and EPS all exceeding targets. The company advanced its Billion Cell Atlas initiative, now over halfway complete, with GSK joining the consortium. Illumina launched the BioInsight platform integrating analysis applications, AI models, and curated biological data, including SpliceAI2 which identified 17% more disease-relevant splice variants than competing models.
Guidance
Management raised full fiscal year 2026 guidance following strong Q3 execution and business momentum. The company stated it remains on track to achieve long-range financial targets, citing continued disciplined execution.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 29, 2026$1.62
est $1.36
+19.1%$1.17B
est $1.15B
+1.1%−18.3%
Jul 30, 2026$1.31
est $1.23
+6.5%$1.16B
est $1.13B
+2.5%+5.3%
Apr 30, 2026$1.15
est $1.07
+7.5%$1.09B
est $1.07B
+1.7%+12.8%
Feb 5, 2026$1.35
est $1.22
+10.7%$1.16B
est $1.12B
+3.6%−10.8%
Oct 30, 2025$1.34
est $1.17
+14.5%$1.08B
est $1.07B
+1.6%+30.0%
Jul 31, 2025$1.19
est $1.02
+16.7%$1.06B
est $1.06B
−0.6%−11.3%
May 8, 2025$0.97
est $0.94
+3.2%$1.04B
est $1.03B
+1.5%−0.8%
Feb 6, 2025$0.86
est $0.92
−6.5%$1.10B
est $1.07B
+3.0%−10.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Illumina stock forecast and analyst price targets

Analysts’ average 12-month price target for Illumina is $261.45, +32.0% from the last close, from 17 firms rating the stock in the last 90 days.

$261.45consensus 12-month target, +32.0% from the last close
Low $200High $310
Buy8
Hold6
Sell3

Each firm’s latest rating in the last 90 days: 17 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13BernsteinHold, maintained——
Nov 5Robert W. BairdHold, maintained$236+19.2%
Nov 2Freedom Capital MarketsHold, maintained$200+1.0%
Nov 2CitiSell, maintained$210+6.1%
Oct 30Stifel NicolausBuy, maintained$300+51.5%
−1.0%average 20-day move after past Accumulation readings
+8.5%average move over the next 20 trading days in the last 5 years
±8.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Illumina seasonality: the next 20 trading days

Over the next 20 trading days from Nov 17, Illumina averaged +8.5% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

+0.3%2021−11.2%2022+36.9%2023+9.5%2024+9.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.7%3 of 5
Next 10 trading days+5.4%3 of 5
Next 15 trading days+6.8%3 of 5
Next 20 trading days+8.5%4 of 5
Next 30 trading days+7.3%3 of 5

For scale, ILMN’s typical 20-trading-day move in either direction is about 8.2%.

Illumina market cap and key statistics

Illumina’s market cap is $29.94B, with a P/E ratio of 35.6 and revenue of $4.54B over the last twelve months.

Valuation

Market cap
$29.94B
P/E ratio
35.6
Forward P/E
33.6
EPS, TTM
$5.81
Gekko Fair Value
$253.75

Trading

Volume
1.52M
Avg volume, 20 days
2.19M
52-week high
$309.35
52-week low
$112.65
Shares outstanding
151.2M

Financials

Revenue, TTM
$4.54B
Profit margin
19.7%
Return on equity
32.4%
Quarterly earnings growth, YoY
+45.9%

Risk and income

Beta
1.45
Typical daily move
±8.4%
Typical 20-day move
±8.2%

Illumina stock news this week

3 headlines about Illumina from the past week, newest first, each linking to the publisher.

Illumina peers

Illumina’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−1.1%Neutral13.7% above
ABTAbbott Laboratories−1.9%Neutral11.1% below
DHRDanaher−1.5%Neutral3.9% above
ISRGIntuitive Surgical−1.5%Neutral16.1% above
MDTMedtronic−0.9%Neutral13.6% below
SYKStryker−1.1%Neutral0.6% above

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Illumina stock FAQ

What is Illumina’s market cap?

Illumina’s market cap is $29.94B at the Nov 16, 2026 close of $198.00, with 151.2M shares outstanding. The shares trade on a P/E ratio of 35.6.

What is the Illumina stock forecast?

The consensus analyst 12-month price target for Illumina is $261.45, +32.0% from the last close. Of the 17 firms that rated the stock in the last 90 days, 8 rate it a buy, 6 a hold and 3 a sell. Gekko doesn’t publish price predictions of its own.

Is Illumina stock overvalued or undervalued?

On Gekko’s estimate Illumina is undervalued: the Nov 16, 2026 close of $198.00 is 22.0% below Gekko Fair Value of $253.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Illumina report earnings next?

Illumina is expected to report on Feb 4, 2027, after the market closes (79 days away). Analysts expect earnings of $1.52 per share on revenue of $1.23B. Illumina beat the earnings estimate in 7 of its last 8 reports, moving 12.5% on average across the report.

What is Illumina’s 52-week high and low?

Illumina’s 52-week high is $309.35 and its 52-week low is $112.65; it closed at $198.00 on Nov 16, 2026, +65.1% over the past year. Over the last five years the shares peaked at $415.94 on Jan 12, 2022.

Is Illumina stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Illumina?

Gekko flagged 1 unusual options signal in Illumina over the last 30 days, with $485K of flagged premium in calls and $751K in puts. The latest, bearish flow, was on Nov 3, 2026 with $1.24M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Illumina the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,476 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.